Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 156 full-time employees. The company went IPO on 2020-04-03. The firm is developing a focused pipeline of oncology candidates. The Company’s product candidates include Azenosertib (ZN-c3), a Wee1 inhibitor for advanced solid tumors and hematological malignancies; ZN-d5, a B-cell lymphoma 2 (BCL-2), inhibitor for hematological malignancies and related disorders; and a heterobifunctional degrader of BCL-xL, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. The firm is evaluating azenosertib and ZN-d5 in multiple ongoing clinical trials and conducting studies to enable an Investigational New Drug (IND), application for its BCL-xL product candidate. The firm is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.